WhaleCreep

Avidity Partners Management LP 13F holdings, Q2 2021

Hedge fundSEC filingsCompare with another fundHoldings as of 2021-06-30, filed 2021-08-16

Avidity Partners Management LP disclosed 112 US equity positions worth $3.7bn in its Q2 2021 13F filing. Its largest position is VRTX at 5.2% of the reported book, followed by ABBV and ARVN. Versus Q1 2021 it opened 54 new positions, added to 23, reduced 23 and exited 35.

$3.7bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
112
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
5.2%
Largest position
The largest single position as a share of the reported equity book.
34.9%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
48
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2021: 54 new, 23 added, 23 reduced, 35 exited

50 of 112
VRTX VERTEX PHARMACEUTICALS INCHealthcare5.2%$192m950,000+206%added
ABBV ABBVIE INCHealthcare4.5%$167m1.48m−29%reduced
ARVN ARVINAS INCHealthcare3.9%$143m1.85m+5.3%added
LLY ELI LILLY & COHealthcare3.5%$130m565,500–new
MRVI MARAVAI LIFESCIENCES HLDGS IHealthcare3.3%$124m2.96m+7.3%added
MRTXEUR MIRATI THERAPEUTICS INC–3.3%$122m753,000+58%added
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare3.1%$115m2.16m+71%added
AVTR AVANTOR INCHealthcare3.1%$113m3.18m−36%reduced
SGENUSD SEAGEN INC–2.7%$101m640,000+11%added
BIOHAVEN PHARMACTL HLDG CO L no ticker–2.3%$85.7m882,500−16%reduced
HO1 HOLOGIC INC–2.2%$80.7m1.21m–new
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.1%$79.2m4.62m+20%added
EPIEUR ESSA PHARMA INC–2.1%$78.6m2.75m−3.2%reduced
EXK EXACT SCIENCES CORPBasic Materials2.0%$73.3m590,000−1.3%reduced
MDT Medtronic PlcHealthcare1.8%$66.4m535,000−48%reduced
NBIX NEUROCRINE BIOSCIENCES INCHealthcare1.8%$66.3m681,000+31%added
NUVB NUVATION BIO INCHealthcare1.8%$64.9m6.97m−7.4%reduced
ARNAEUR ARENA PHARMACEUTICALS INC–1.7%$64.3m943,000+4.9%added
BIIB BIOGEN INCHealthcare1.7%$63.7m183,900–new
NEO NEOGENOMICS INCHealthcare1.7%$61.7m1.37m–new
NTLA INTELLIA THERAPEUTICS INCHealthcare1.7%$61.5m380,000–new
NBP NOVABRIDGE BIOSCIENCESHealthcare1.7%$61.2m729,000−45%reduced
CTLTEUR CATALENT INC–1.6%$58.4m540,000−3.6%reduced
STTK SHATTUCK LABS INCHealthcare1.5%$56.2m1.94m+46%added
CNC CENTENE CORP DELHealthcare1.5%$54.8m751,200–new
HORIZON THERAPEUTICS PUB L no ticker–1.4%$53.2m568,000−2.2%reduced
2655787D BLUEPRINT MEDICINES CORP–1.3%$49.5m563,200+3.2%added
NTRA NATERA INCHealthcare1.3%$49.5m436,000+10%added
SHC SOTERA HEALTH COHealthcare1.3%$46.3m1.91m+65%added
XLRN ACCELERON PHARMA INC–1.2%$45.0m358,500+11%added
IDYA IDEAYA BIOSCIENCES INCHealthcare1.2%$43.4m2.07m+41%added
UTHR UNITED THERAPEUTICS CORP DELHealthcare1.1%$42.4m236,400–new
BBIO BRIDGEBIO PHARMA INCHealthcare1.1%$41.0m673,400−17%reduced
ATEC ALPHATEC HLDGS INCHealthcare1.1%$40.2m2.62m+12%added
TREUR TRILLIUM THERAPEUTICS INC–1.1%$39.8m4.11m+2.2%added
CYTEIR THERAPEUTICS INC no ticker–1.0%$38.7m1.81m–new
CMPS COMPASS PATHWAYS PLCHealthcare1.0%$38.1m1.00m–new
CAH CARDINAL HEALTH INCHealthcare1.0%$37.3m654,200−55%reduced
KDMN KADMON HLDGS INC–1.0%$36.0m9.29m−2.6%reduced
DVAX DYNAVAX TECHNOLOGIES CORP–0.9%$33.5m3.40m−2.9%reduced
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare0.9%$33.1m195,000−54%reduced
INSM INSMED INCHealthcare0.9%$32.7m1.15m–new
SPNEUSD SEASPINE HLDGS CORP–0.8%$31.3m1.52m–new
LFST LIFESTANCE HEALTH GROUP INCHealthcare0.8%$30.6m1.10m–new
IPSC CENTURY THERAPEUTICS INCHealthcare0.8%$29.4m1.00m–new
LEGN LEGEND BIOTECH CORPHealthcare0.7%$25.7m625,000–new
IMCR IMMUNOCORE HLDGS PLCHealthcare0.6%$23.5m601,000+9.3%added
ACET ADICET BIO INCHealthcare0.6%$23.2m2.25m+0.9%added
ACAD ACADIA PHARMACEUTICALS INCHealthcare0.6%$22.9m940,000–new
GRPH GRAPHITE BIO INC–0.6%$22.6m735,500–new

Exited since Q1 2021

35 rows
AZN ASTRAZENECA PLC5.1%$182m
ISRG INTUITIVE SURGICAL INC2.9%$103m
BHC BAUSCH HEALTH COS INC1.7%$60.0m
ZBH ZIMMER BIOMET HOLDINGS INC1.5%$52.2m
CCXIEUR CHEMOCENTRYX INC1.3%$48.2m
ABMDEUR ABIOMED INC1.2%$42.2m
INO INOVIO PHARMACEUTICALS INC1.0%$37.2m
CI THE CIGNA GROUP0.9%$32.6m
ATHIRA PHARMA INC no ticker0.9%$30.9m
CGEM CULLINAN THERAPEUTICS INC0.8%$29.5m
ORGO ORGANOGENESIS HLDGS INC0.7%$26.7m
KINIKSA PHARMACEUTICALS LTD no ticker0.7%$24.6m
CRIS CURIS INC0.6%$23.2m
AUPH AURINIA PHARMACEUTICALS INC0.6%$23.2m
1K0 IGM BIOSCIENCES INC0.6%$22.5m
BOLT BOLT BIOTHERAPEUTICS INC0.6%$21.5m
CMRXEUR CHIMERIX INC0.6%$21.5m
BVS BIOVENTUS INC0.5%$19.2m
SIGILON THERAPEUTICS INC no ticker0.5%$19.0m
COLL COLLEGIUM PHARMACEUTICAL INC0.5%$17.5m
KEZAR LIFE SCIENCES INC no ticker0.3%$11.4m
ADMSEUR ADAMAS PHARMACEUTICALS INC0.3%$10.6m
AFFIMED N V no ticker0.3%$10.3m
MERUS N V no ticker0.3%$10.2m
IMTX IMMATICS N.V0.3%$9.9m
430 TERNS PHARMACEUTICALS INC0.2%$8.8m
EVELO BIOSCIENCES INC no ticker0.2%$8.6m
VESPER HEALTHCARE ACQSTN COR no ticker0.2%$6.9m
ARYA SCIENCES ACQUISITION CO no ticker0.2%$6.9m
ARGX ARGENX SE0.2%$5.5m
MEDICUS SCIENCES ACQUISITION no ticker0.1%$5.1m
COGT COGENT BIOSCIENCES INC0.1%$3.7m
EYPT EYEPOINT INC0.07%$2.4m
ANNX ANNEXON INC0.05%$1.9m
AMWL AMERICAN WELL CORP0.03%$1.2m

Sector mix

  • Healthcare63.5%
  • Unclassified33.0%
  • Basic Materials2.0%
  • Technology1.4%
  • Consumer Cyclical0.1%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters